Histone deacetylases and inhibitors in diabetes mellitus and its complications.
Biomed Pharmacother
; 177: 117010, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38941890
ABSTRACT
Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia, with its prevalence linked to both genetic predisposition and environmental factors. Epigenetic modifications, particularly through histone deacetylases (HDACs), have been recognized for their significant influence on DM pathogenesis. This review focuses on the classification of HDACs, their role in DM and its complications, and the potential therapeutic applications of HDAC inhibitors. HDACs, which modulate gene expression without altering DNA sequences, are categorized into four classes with distinct functions and tissue specificity. HDAC inhibitors (HDACi) have shown efficacy in various diseases, including DM, by targeting these enzymes. The review highlights how HDACs regulate ß-cell function, insulin sensitivity, and hepatic gluconeogenesis in DM, as well as their impact on diabetic cardiomyopathy, nephropathy, and retinopathy. Finally, we suggest that targeted histone modification is expected to become a key method for the treatment of diabetes and its complications. The study of HDACi offers insights into new treatment strategies for DM and its associated complications.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Complications
/
Diabetes Mellitus
/
Histone Deacetylase Inhibitors
/
Histone Deacetylases
Limits:
Animals
/
Humans
Language:
En
Journal:
Biomed Pharmacother
Year:
2024
Document type:
Article